High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial...

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Severe hyperlipidemia poses significant cardiovascular risks.
• Statins are primary agents for managing dyslipidemia.
• Understanding differential responses to statins is crucial for personalized therapy.

Purpose of the Study:

• To identify clinical and biochemical factors influencing high-density lipoprotein (HDL) and triglyceride response to simvastatin and atorvastatin.
• To compare the efficacy of simvastatin and atorvastatin in severe hyperlipidemia.

Main Methods:

• A randomized open-trial design involving 150 patients with severe hyperlipidemia.
• Assessment of lipid profiles, including HDL, triglycerides, apolipoprotein A1, apolipoprotein B, and LDL.
• Analysis of dose-response relationships and treatment effects.

Main Results:

• Triglyceride reduction was associated with HDL:apolipoprotein A1 levels, changes in apolipoprotein B, and statin dosage.
• Increased HDL levels were dependent on baseline LDL, LDL changes, statin dosage, and specifically simvastatin therapy.
• Both simvastatin and atorvastatin demonstrated efficacy in managing hyperlipidemia parameters.

Conclusions:

• Specific biochemical markers and baseline lipid levels predict statin response in severe hyperlipidemia.
• Simvastatin may offer advantages in increasing HDL compared to atorvastatin in certain patient profiles.
• Personalized statin selection based on individual patient characteristics can optimize lipid management.